Portal de Periódicos da CAPES

Immunoglobulin signature predicts risk of post-acute COVID-19 syndrome

2022; Nature Portfolio; Volume: 13; Issue: 1 Linguagem: Inglês

10.1038/s41467-021-27797-1

2041-1723

Carlo Cervia, Yves Zurbuchen, Patrick Taeschler, Tala Ballouz, Dominik Menges, Sara Hasler, Sarah Adamo, Miro E. Raeber, Esther Bächli, Alain Rudiger, Melina Stüssi‐Helbling, Lars C Huber, Jakob Nilsson, Ulrike Held, Milo A. Puhan, Onur Boyman,

COVID-19 and Mental Health

Abstract Following acute infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) a significant proportion of individuals develop prolonged symptoms, a serious condition termed post-acute coronavirus disease 2019 (COVID-19) syndrome (PACS) or long COVID. Predictors of PACS are needed. In a prospective multicentric cohort study of 215 individuals, we study COVID-19 patients during primary infection and up to one year later, compared to healthy subjects. We discover an immunoglobulin (Ig) signature, based on total IgM and IgG3 levels, which – combined with age, history of asthma bronchiale, and five symptoms during primary infection – is able to predict the risk of PACS independently of timepoint of blood sampling. We validate the score in an independent cohort of 395 individuals with COVID-19. Our results highlight the benefit of measuring Igs for the early identification of patients at high risk for PACS, which facilitates the study of targeted treatment and pathomechanisms of PACS.